The clip compares Sinovac and AstraZeneca, focusing on side effects viewers may worry about, including neurological symptoms and thrombosis with thrombocytopenia syndrome (TTS). The video reflects an earlier phase of the pandemic; do not read it as a current vaccine ranking or advice about which product to receive today.
Common reactions and specific safety signals
Common post-vaccination reactions and serious adverse events are different issues. Injection-site pain or temporary symptoms that can occur after vaccination are not the same as thrombosis with thrombocytopenia syndrome (TTS). WHO describes TTS as a rare but serious event and notes reports after some adenovirus-vector COVID-19 vaccines, including AstraZeneca and Janssen.
Why this video cannot determine whether a vaccine is “worth it”
Comparing risks requires specifying the product, formulation, period, number of doses, population, and denominator used for event rates. Data from early vaccine rollouts do not represent the current risk for every vaccine. A decision about whether a product is “worth it” for an individual also depends on disease risk and personal medical history.
Decisions and symptoms that need assessment
WHO provides guidance for health professionals on evaluating and managing TTS after vaccination. It is not a guide for self-diagnosis or treatment. If you have severe or unusual symptoms after vaccination, contact a health service promptly and bring the vaccine name and vaccination date. For current schedules and products available in Thailand, follow current Thai guidance.
Original video
Watch the original cited by this article: Open on YouTube